Søknadsresultater og tidligere tildelinger
Oversikt over prosjekter som har oppnådd finansiering gjennom KLINBEFORSK siden første utlysning gjennomført i 2016.
Nedenfor gis det en oversikt over prosjekter som har oppnådd finansiering gjennom KLINEBFORSK siden programmets oppstart i 2016. Prosjektene er gruppert i nedtrekksmenyen etter utlysningsår.
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill. kr) |
|---|---|
| A clinical phase I program targeting hematological malignancies with adaptive NK cells - Karl-Johan Malmberg, Oslo universitetssykehus | 15.7 |
| Effectiveness of novel criss-sectorial collaborative treatment pathway for chronic pain patients - Astrid Woodhouse, St. Olavs hospital | 23.7 |
| Phase I/II trial evaluating CAR T cell therapy against prostate cancer - Jon Amund Kyte, Oslo universitetssykehus | 13.8 |
| RCT of ketamine treatment duration for severe depression - Ole A. Andreassen, Sykehuset Østfold | 24.9 |
| The Strong@Home trial - Peder Langeland Myhre, Akershus universitetssykehus | 23.6 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill. kr) |
|---|---|
| Proton therapy in sarcoma: establishing a new national standard of care | 25.0 |
| Proton radioteherapy in Norwegian head and neck cancer patients (PRORADNOR) - Hanne Astrid Eide, Oslo universitetssykehus | 24.9 |
I tillegg er studieprogrammet IMPRESS-Norway videreført med 20 mill. kroner hvert år for perioden 2025-27.
|
Tittel, prosjektleder, koordinerende institusjon |
Sum (mill. kr) |
|---|---|
|
The effect of topical tranexamic acid on postoperative complications in soft tissue plastic surgery. A multicenter randomized controlled trial - Kjersti Ausen, St. Olavs hospital |
9.6 |
|
Multicentre triple blind, placebo controlled, parallel group studies of atorvastatin in respectively episodic and chronic migraine - Knut Hagen, St. Olavs hospital |
13.2 |
|
Candesartan for prevention of cluster headache (CandClus2): Two multicenter, randomized, placebo-controlled, triple blind studies in patients with the episodic or the chronic form - Erling Andreas Tronvik, St. Olavs hospital |
19.9 |
|
Surgery versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR (Scar) - Michael Bretthauer, Oslo universitetssykehus |
20.0 |
|
Scandinavian trial of Uncomplicated Aortic Dissection Therapy (SUNDAY Trial) - Eric Dorenberg, Oslo universitetssykehus |
10.9 |
|
The Safety of Intravenous thrombolysis in acute ischemic stroke patients with recent ingestion of Factor Xa-inhibitors Trial - Guri Hagberg, Oslo universitetssykehus |
20.0 |
|
Antibiotic therapy in viral airway infections - Magnus Nakrem Lyngbakken, Akershus universitetssykehus |
17.5 |
|
PALLiative radiotherapy in symptomatic pelvic SOFT tissue tumors (PALLSOFT) - Harald Bull Ragnum, Sykehuset Telemark |
20.0 |
|
Tittel, prosjektleder, koordinerende institusjon |
Sum (mill. kr) |
|---|---|
|
Personalised training for people with rare Neuromuscular Disorders (PETRA-NMD) - Kristin Ørstavik, Oslo universitetssykehus |
17.1 |
|
NAD-HD: A randomized clinical trial of nicotinamide riboside in Huntington’s disease - Lasse Pihlstrøm, Oslo universitetssykehus |
13.0 |
|
Rituximab for improving lung function in Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency - Børre Fevang, Oslo universitetssykehus |
14.9 |
|
NADAPT - A Randomized Double-blind Trial of NAD Replenishment Therapy in Atypical Parkinsonism - Charalampos Tzoulis, Helse Bergen |
20.0 |
Tildeling etter åpen utlysning i 2022:
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill. kr) |
|---|---|
| Comprehensive Evaluation of Two Second-Line Therapies for Immune Thrombocytopenia - Waleed Ghanima, Sykehuset Østfold | 19.9 |
| CRISPR-Cas9 gene therapy for STAT1 Gain-of-Function disease - Emma Haapaniemi, Oslo universitetssykehus | 19.9 |
| The NORwegian atrial fibrillation self-SCREENing trial (NORSCREEN) - Sigrun Halvorsen, Oslo universitetssykehus | 19.7 |
| Can SGLT2 Inhibition Preserve Structure and Function in Transplanted Kidneys? - Trond Geir Jenssen, Oslo universitetssykehus | 17.6 |
| CAR-T cell therapy targeting Ewing Sarcoma, Jon Amund Kyte, Oslo universitetssykehus | 19.8 |
| Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease - Hans Olav Ueland, Helse Bergen | 19.8 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| The Covideo study - Einar Røshol Heiervang, Sykehuset Innlandet | 18.4 |
| Comparing enhanced cognitive-behavior therapy and family-based treatment for adolescents with an eating disorder - Øyvind Rø, Oslo universitetssykehus | 20.0 |
| Interventions against long COVID in Norway (ReCover) - Nina Langeland, Helse Bergen | 20.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill. kr) |
|---|---|
| SAINT: SAfe INduction of labor Trial - Trond Melbye Michelsen, Oslo universitetssykehus | 20.0 |
| Registry-based randomized trial of glucocorticoid replacement in adrenal insufficiency - Eystein Sverre Husebye, Helse Bergen | 12.3 |
| NO-PARK: a phase II randomized controlled trial of nicotinamide riboside in early Parkinson’s disease - Charalampos Tzoulis, Helse Bergen | 20.0 |
| Painful Inflammatory Carpometacarpal-1 OsteoArthritis Treated with Intraarticular Steroids, Saline or Occupational therapy: The PICASSO trial - Ida Kristin Haugen, Diakonhjemmet sykehus AS | 18.7 |
| A randomized, controlled, multicenter clinical trial of immediate tumor-directed therapy versus initial conservative management in older patients with non-metastatic, high-risk prostate cancer - Sven Löffeler, Sykehuset i Vestfold | 19.3 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Kirurgisk behandling av lipødem - Hildur Skuladottir, Haraldsplass Diakonale Sykehus | 20.0 |
| eBATTLE Obesity (eHealth BehAvioral TreaTment of adoLEscent Obesity - 2-month low-energy-diet followed by 1-yr cognitive behavioral therapy with or without semaglutide) - Jøran Hjelmesæth, Sykehuset i Vestfold | 20.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| RAM-MS - Lars Bø, Helse Bergen | 20.0 |
| IMPRESS-Norway - Åslaug Helland, Oslo universitetssykehus | 10.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Agonist treatment with Lisdexamemphetamine for amphetamines dependence (ATLAS4dependence) - Kjell Arne Johansson, Helse Bergen | 20.0 |
| The Norwegian Anti-Dementia Drig Trial Platform (NORADD-TP) - Dag Årsland, Helse Stavanger | 20.0 |
| Effects of long-term ventialation support in ALS on quality of life in patients and their families - Ole Bjørn Tysnes, Helse Bergen | 19.9 |
| Clinical evaluation of CD37 CAR-T for acute myeloid leukemia - Bjørn Tore Gjertsen, Helse Bergen | 20.0 |
| InsighT-1: A phase I first-in-man trial of genetically modified TdT TCR T-cells in children and adults with T- and B-cell acute lymphoblastic leukimia - Jochen Büchner, Oslo universitetssykehus | 20.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Randomized trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab plus platinum and etoposide in extensive stage small-cell lung cancer - Bjørn Henning Grønberg, St. Olavs hospital | 19.3 |
| The NO-ALS Study. Effect of Nikotinamide Riboside and Pterostilben in Amyotrophic Lateral Sclerosis - Ole-Bjørn Tysnes, Helse Bergen | 18.9 |
| Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT) - Torgeir Bruun Wyller, Oslo universitetssykehus | 19.7 |
| TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) - Anne Hege Aamodt, Oslo universitetssykehus | 6.3 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Evaluation of a Norwegian model of an Intensive Habilitation Program for young Children with early Brain Damage - Jon Sverre Skranes, Sørlandet sykehus | 19.8 |
| IMPRESS-Norway – Improving public cancer care by implementing precision medicine in Norway - Åslaug Helland, Oslo universitetssykehus | 50.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| The NOR-Solidarity trial - Andreas Barratt-Due, Oslo universitetssykehus | 10.0 |
| EU-SolidAct - Marius Trøseid, Oslo universitetssykehus | 10.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Study of mesenchymal autologous stem cells as regenerative treatment for multiple sclerosis (SMART-MS) - Lars Bø, Helse Bergen | 12.3 |
| The Norwegian Tenecteplase Stroke Trial 2 (NOR-TEST 2) - Halvor Næss, Helse Bergen | 19.9 |
| Durvalumab after radiotherapy - the DART-study - Åslaug Helland, Oslo universitetssykehus | 14.2 |
| Faecal transplantation for irritable bowel syndrome - first Phase III clinical trial - Rasmus Goll, Universitetssykehuset Nord-Norge | 19.4 |
| Repeated advanced cognitive training in MCI (the REACT-MCI study) - Susanne M. Sørensen Hernes, Sørlandet sykehus | 19.8 |
| Improving treatment of anterior curciate ligament tears in NORWAY with register-RCTs - Rune Bruhn Jacobsen, Akershus universitetssykehus | 17.8 |
| Dietary interventio to delay deterioration if neuronal function in Ataxia Telangiectasia - Hilde Nilsen, Akershus universitetssykehus | 6.4 |
| Ambroxol in early and prodromal Dementia with Lewybodies - Arvid Rongve, Helse Fonna | 20.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Ocrelizumab vs Rituximab off-label at the onset of relapsing MS disease: The OVERLORD MS-study - Kjell-Morten Myhr, Helse Bergen | 19.2 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
| The Norwegian Trial of Physical Exercise After Myocardial Infarction - NOREx - Kåre Bønaa, St. Olavs hospital | 20.0 |
| Acceptance and commitment therapy with and without enhanced mindfulness training for chronic pain - Petter Christian Borchgrevink, St. Olavs hospital | 19.9 |
| Proteasome blockade to sensitize glioblastoma with unmethylated MGMT promoter to temozolomide chemotherapy - Dorota Goplen, Helse Bergen | 15.8 |
| Fecal Transplantation for Primary Clostridium Difficile Infection - Michael Bretthauer, Oslo universitetssykehus | 19.9 |
| Urine based surveillance of bladder cancer patients - Guro Lind, Oslo universitetssykehus | 20.0 |
| The ReSScue study; clinical and mechanistic effects of transplanting a standard cultivated gut microbiome in patients with Systemic Sclerosis - Øyvind Molberg, Oslo universitetssykehus | 19.0 |
| The REMNANT study – does early treatment of relapse increase survival in myeloma? - Fredrik H. Schjesvold, Oslo universitetssykehus | 20.0 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Sphenopalatine ganglion block in chronic migraine (MIBLOCK) - Anders Mattias Linde, St. Olavs hospital | 18.7 |
| Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing – INSTAR - Henrik Døllner, St. Olavs hospital | 20.0 |
| Immunotherapy for Hematological Malignancies; A Path to Cure - Henrik Hjorth-Hansen, St. Olavs hospital | 5.7 |
| Changing the specialist mental health care - Gerd Kvale, Helse Bergen | 20.0 |
| Improved prediction of outcome by global strain and mechanical dispersion in patients with myocardial infarction, heart failure and primary prophylactic internal defibrillator - Thor Edvardsen, Oslo universitetssykehus | 17.8 |
| BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function - Dan Atar, Oslo universitetssykehus | 15.0 |
| Establishment of Molecular profiling for Individual clinical routine Treatment decisions in Early Breast Cancer (EMIT) - Bjørn Naume, Oslo universitetssykehus | 20.0 |
| BACK-TO-BASIC - a study of the effect of infliximab on patients with long-term lower back pain and Modic changes - John-Anker Zwart, Oslo universitetssykehus | 17.9 |
| Tittel, prosjektleder, koordinerende institusjon | Sum (mill.kr) |
|---|---|
| Tenecteplase in wake-up ischaemic stroke trial (TWIST) - Ellisiv B. Mathiesen, Universitetssykehuset Nord-Norge | 15.5 |
| A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in Metastatic Melanoma: Identification of predictive markers of response - Oddbjørn Straume, Helse Bergen | 17.6 |
| Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple sclerosis (RAM-MS) - Lars Bø, Helse Bergen | 20.0 |
| PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA2) - Torbjørn Omland, Akershus universitetssykehus | 20.0 |
| The Nor-DRUM STUDY: assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring - Espen Andre Haavardsholm, Diakonhjemmet Sykehus AS | 12.4 |
| The ASAC-study: Acetylsalisylic Acid as Secondary Prevention in Colorectal Cancer - Bjørn Atle Bjørnbeth, Oslo universitetssykehus | 13.8 |
| The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study - Håvard Ove Skjerven, Oslo universitetssykehus | 19.3 |